Literature DB >> 2431776

Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.

T Colombo, C Rossi, M D'Incalci.   

Abstract

In this study we show that cytarabine given simultaneously with 5-aza-2'-deoxycytidine (Aza-dC) antagonized Aza-dC activity against L1210 mouse leukemia. This antagonism was seen after a single dose (on Day 3 or Day 5 after tumor implant) and after repeated doses. This observation suggests caution in combining cytarabine with Aza-dC in the treatment of human leukemias.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2431776

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  3 in total

Review 1.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

2.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18

3.  Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Authors:  Christopher B Benton; Farhad Ravandi; Michael Andreeff; Tapan Kadia; Vivian Ruvolo; Peng Qiu; David A Wheeler; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2013-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.